Mirabella Financial Services LLP Acquires Shares of 89,849 Edwards Lifesciences Co. (NYSE:EW)

Mirabella Financial Services LLP acquired a new position in shares of Edwards Lifesciences Co. (NYSE:EW) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 89,849 shares of the medical research company’s stock, valued at approximately $5,929,000.

Several other institutional investors have also modified their holdings of the company. LRI Investments LLC acquired a new position in Edwards Lifesciences in the first quarter valued at approximately $67,000. Lazard Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 89.6% in the 1st quarter. Lazard Asset Management LLC now owns 93,629 shares of the medical research company’s stock valued at $8,946,000 after buying an additional 44,257 shares in the last quarter. Kennedy Capital Management LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at $2,440,000. 2Xideas AG raised its stake in Edwards Lifesciences by 25.9% during the 1st quarter. 2Xideas AG now owns 196,508 shares of the medical research company’s stock worth $18,778,000 after acquiring an additional 40,465 shares in the last quarter. Finally, Vancity Investment Management Ltd lifted its position in Edwards Lifesciences by 273.3% in the first quarter. Vancity Investment Management Ltd now owns 142,121 shares of the medical research company’s stock valued at $13,581,000 after acquiring an additional 104,047 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. Robert W. Baird reduced their price objective on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Evercore ISI lowered their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Piper Sandler reduced their price target on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Oppenheimer reiterated an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Hold” and an average target price of $75.67.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 40,000 shares of company stock valued at $2,657,000 in the last 90 days. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.2 %

Shares of Edwards Lifesciences stock opened at $70.64 on Monday. The company has a 50-day moving average of $67.70 and a two-hundred day moving average of $75.59. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $41.66 billion, a PE ratio of 10.17, a price-to-earnings-growth ratio of 3.96 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the business posted $0.59 EPS. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.